Lytix Biopharma Increases Capital for Cancer Innovations

Lytix Biopharma AS (DE:6BG) has released an update.

Lytix Biopharma AS has successfully raised NOK 111.3 million through a private placement and a retail offering, increasing its share capital to NOK 6,815,943.40. This move supports the company’s ongoing development of innovative cancer treatments, including its lead product, LTX-315. The new shares are set to be registered with the Norwegian Central Securities Depository shortly.

For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.